Assessing the equilibration of the unbound drug concentrations across the blood-brain barrier (K p,uu ) has progressively replaced the partition coefficient based on the ratio of the total concentration in brain tissue to blood (K p ). Here, in vivo brain distribution studies were performed on a set of central nervous system (CNS)-targeted compounds in both rats and P-glycoprotein (P-gp) genetic knockout mice. Several CNS drugs are characterized by K p,uu values greater than unity, inferring facilitated uptake across the rodent blood-brain barrier (BBB). Examples are shown in which K p,uu also increases above unity on knockout of P-gp, highlighting the composite nature of this parameter with respect to facilitated BBB uptake, efflux, and passive diffusion. Several molecules with high K p,uu values share common structural elements, whereas uptake across the BBB appears more prevalent in the CNS-targeted drug set than the chemical templates being generated within the current lead optimization paradigm. Challenges for identifying high K p,uu compounds are discussed in the context of acute versus steady-state data and cross-species differences. Evidently, there is a need for better predictive models of human brain K p,uu .
Introduction
Drug distribution across the blood-brain barrier (BBB) forms a central element in linking pharmacokinetics to the pharmacological action of xenobiotics within the central nervous system (CNS) (Reichel, 2015) . Unbound drug that crosses the BBB into brain extracellular fluid (ECF) is available to distribute to the biophase or bind nonspecifically within the lipid-rich components of brain tissue . Recent examples linking unbound drug brain concentrations with potency, target engagement or effect (Large et al., 2009; Watson et al., 2009; Liu and Chen, 2015) have helped to transition the thinking of CNS drug discovery scientists away from total concentration measurements and more toward unbound drug concentrations. Similarly, interpreting brain distribution has shifted away from the brain-to-blood partition ratio based on total concentrations (K p ) toward the unbound ratio (K p,uu ) comprising brain ECF and unbound blood concentrations (Liu and Chen, 2015) . K p,uu is a steady-state distribution term denoting the unbound concentration gradient across the BBB (Gupta et al., 2006; Hammarlund-Udenaes et al., 2008) . If K p,uu is substantially lower than unity, then drug passage across the BBB is restricted by some factor, such as poor permeability (e.g., atenolol; Summerfield et al., 2007) or carrier-mediated efflux (Loryan et al., 2014) . The most widely recognized BBB efflux transporter for reducing brain K p,uu is P-glycoprotein (P-gp), which exerts its effects on many chemical templates (Raub, 2006) . Much of the founding in vivo work characterizing P-gp efflux relied on K p measurements; however, this parameter in itself does not indicate whether a drug molecule is the subject of active transport; indeed, additional measurements are required, such as determining K p in an in vivo transporter knockout model (chemical or genetic) or determining the P-gp efflux ratios in an in vitro system. A K p,uu value approaching unity suggests that passive diffusion is an important distribution property of the drug molecule, or that multiple carrier-mediated processes are balanced (e.g., influx and efflux). Although K p,uu alone cannot distinguish these two scenarios, concentration dependency in this value or the permeability-surface product might suggest transporter involvement (Cisternino et al., 2013) . Finally, a K p,uu value in excess of unity would suggest facilitated transfer of unbound drug across a cellular barrier and the establishment of a concentration gradient. An example of this is gabapentin, where the uptake into brain intracellular fluid (Fridén et al., 2007) supported the involvement of LAT1 carrier-mediated transport (Su et al., 1995) .
Fewer literature examples are available demonstrating uptake into the CNS relative to drug efflux; presumably, this is because drug efflux has a far more negative impact on drug dx.doi.org/10.1124/jpet.116.232447. s This article has supplemental material available at jpet.aspetjournals.org. efficacy measurements during lead optimization and early drug development and is therefore identified more readily in favorable chemical templates. However, K p,uu provides a powerful tool for probing the prevalence of facilitated uptake in CNS drugs or lead optimization compounds and whether there are any key structural features or physicochemical properties that promote the passage of unbound drug across the BBB. In this study, we evaluated K p,uu across approximately 50 CNS-targeted compounds. These K p,uu values were derived from steady-state intravenous CNS penetration studies in rodents [rat, mdr1a/b(2/2) mice, and mdr1a/b(1/1) mice] to yield K p, values which were then corrected for nonspecific binding to blood and brain. Intracerebral microdialysis was performed on two examples in which K p,uu was substantially greater than unity (bupropion and clozapine) with paracetamol included as a control (e.g., K p,uu % 1). An assessment of K p,uu across the lead optimization space within GlaxoSmithKline (GSK) is also presented as a guide to the likelihood of other structural hotspots promoting increased brain distribution of unbound drug. In this case, brain distribution information was collated from both steady-state and acute CNS penetration studies.
Materials and Methods
Compound Selection. Fifty-three molecules were examined in the CNS compound set (Supplemental Table 1 for structures) and were selected on the basis of their spread in physicochemical properties (Summerfield et al., 2006 Animals. Adult male Sprague-Dawley (SD) rats (body weight 274-376 g; Charles River UK Ltd., Tranent Edinburgh, Scotland) were used. Male FVB mdr1a/b(2/2) knockout mice and genetically matched mdr1a/b(1/1) wild-type expressing P-gp were purchased from Taconic Farms, Inc. (Germantown, NY). Mouse unbound brain and blood fraction determinations by means of equilibrium dialysis were conducted in male CD-1 mice (Charles River Laboratories, Margate, UK); this mouse strain was selected based on availability together with the fact that internal and external work has showed little impact in nonspecific brain binding across species (Summerfield et al., 2008) and within strain (Kalvass and Maurer, 2002) . All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals.
Preparation for Mouse Steady-State Intravenous Brain Distribution Studies. Each mouse (at least 6 weeks old at the time of surgery) was cannulated via the jugular vein (for drug administration) while under isoflurane anesthesia, with the cannula exteriorized at the back of the neck. Animals were placed in a jacket and tether counterbalance system and allowed to recover for at least 3 days prior to dosing. Three male control mdr1a/b (1/1) and three male mdr1a/b (2/2) knockout mice were dosed with each compound.
The dose solution for each test compound was prepared on the day of dosing using an appropriate formulation for intravenous administration. The infusion rate and infusion time required to reach steady-state blood concentrations (taken as at least 3.5 half-lives) were determined separately for each compound, and were based on prior studies to establish the intravenous pharmacokinetics. Blood samples (25 ml) were taken from the tail vein at 0.5-hour intervals during the last 2 hours of the infusion to confirm steady-state blood concentrations had been achieved. At the end of the infusion period, the mice were decapitated and the brain removed and homogenized with an equal weight of purified water (ELGA maxima; ELGA LabWater, High Wycombe, UK). Triplicate weighed aliquots (50 ml) of brain homogenate were stored at ca. 280°C prior to HPLC/tandem mass spectrometry (MS/MS) analysis. Samples were extracted by a method based on protein precipitation using acetonitrile (250 ml containing a suitable internal standard). Brain concentrations were corrected for residual blood volume using 15 ml/g of brain tissue as the vascular space (Brown et al., 1986) .
Preparation for Rat Steady-State Intravenous Brain Distribution Studies. Adult male SD rats (body weight 274-376 g; Charles River UK Ltd.) were used. Each rat was cannulated via the jugular vein (for drug administration) and femoral vein (for blood sampling) while under isoflurane anesthesia, the cannulae being exteriorized at the back of the neck. Animals were placed in a jacket and tether and allowed to recover for at least 2 days prior to dosing. The dose solution for each test compound was prepared on the day of dosing using an appropriate formulation for intravenous administration. Three rats were dosed for each compound. The infusion rate and infusion time were determined separately for each compound. Blood samples were taken at 0.5-hour intervals during the last 2 hours of the infusion to confirm steady-state blood concentrations had been achieved. At the end of the infusion period, the rats were exsanguinated and decapitated, and the brain was removed. Blood samples (ca. 80 ml) were collected into tubes containing K 2 EDTA as anticoagulant and aliquoted immediately after collection. An aliquot (50 ml) of each blood sample was diluted with an equal volume of purified water and stored at ca. 280°C to await analysis. Each brain was homogenized with an equal weight of purified water (ELGA maxima; ELGA LabWater, High Wycombe, UK). Weighed aliquots (50 ml) of brain homogenate were taken and stored at ca. 280°C prior to HPLC/MS/MS analysis. Samples were extracted by a method based on protein precipitation using acetonitrile (250 ml containing a suitable internal standard). Brain concentrations were corrected for residual blood volume using 15 ml/g as the vascular space (Brown et al., 1986) .
Preparation for Steady-State Intravenous In Vivo Brain Microdialysis Studies. Adult male SD rats (body weight 274-376 g; Charles River UK Ltd.) were used. Prior to surgery, rats received antibiotic (ampicillin or Oxytetracycline) and analgesic (carprofen). Under isoflurane anesthesia, rats were cannulated via a femoral vein into the vena cava (for drug administration) and jugular vein (for blood sampling) (Griffiths et al., 1996) . Following venous cannulation, animals were placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA), and a 20-mm midline incision was made to expose the skull surface. The periosteum was infiltrated with local anesthetic (0.15 ml of mepivacaine hydrochloride) and reflected to expose the bregma. Measurements were taken from the bregma using appropriate anterior and lateral stereotaxic coordinates (anterior, 13.2 mm; lateral, 11.2 mm), and a hole was drilled for the guide probe. Four further holes were drilled in the skull surface to enable fixing screws to be inserted. The guide probe was lowered (ventral, -2.0 mm; all coordinates according to Pellegrino et al., 1979) and cemented into position, and the was skin sutured around the headcap as previously described (Criado et al., 2003) . Jugular and femoral cannulae were exteriorized at the back of the neck. Animals were placed in jackets and collars, housed individually, and allowed to recover for 72 hours prior to dosing.
In vivo Studies to Determine the Concentration of Test Compounds in Blood, Brain, and Cerebrospinal Fluid Following Intravenous Administration to Steady State. Microdialysis probes (CMA11, 2-mm probe length; CMA Microdialysis, Kista, Sweden) perfused with artificial cerebrospinal fluid (aCSF; 145 mM Uptake of CNS Drugs and Candidates across the BBB NaCl, 2.7 mM KCl, 1.2 mM CaCl 2 .2H 2 0, 1.0 mM MgCl 2 .6H 2 0, 2.0 mM Na 2 HPO 4 , pH 7.4) at a flow rate of 1.5 ml/min were inserted through the previously implanted guide cannula into the cortex. Rats were placed in Perspex bottom Raturn bowls (BASi, West Lafayette, IN), were freely moving, and had access to food and water ad libitum throughout the experiment. Probes were dialyzed with aCSF for at least 1 hour prior to dosing to allow tissue equilibration (Chaurasia et al., 2007) . Dose solutions of test compounds and reference solutions for retrodialysers were prepared on the day of dose administration and filtered before administration. Aliquots of dose solutions and reference solutions were collected prefilter, postfilter, and postdose and stored at approximately 280°C prior to analysis by HPLC-MS/MS. Dose solutions of test compounds were prepared in an appropriate formulation for intravenous administration. Test compounds were administered as constant rate intravenous infusions over 6 or 8 hours via the femoral vein cannula. The infusion rate and infusion time were determined for each test compound from pharmacokinetic data generated previously "in house" (data not shown) to achieve targeted steady-state blood concentrations (C ss , range 0.1-1 mg/ml) designed to optimize quantitative measurement of test compounds. The actual dose rates used (mg/kg/h) and the subsequent blood clearances (ml/min/kg) were as follows: acetaminophen, 2887 6 12 mg/kg/h and 45 6 2 ml/min/kg; clozapine, 1474 6 19 mg/kg/h and 115 6 13 ml/min/kg; and bupropion, 1826 6 106 mg/kg/h and 127 6 23 ml/min/kg. Reference solutions were prepared at a concentration of 250 ng/ml retrodialyser in aCSF containing 0.1% (v/v) dimethylsulfoxide. Reference solutions were administered via the probe prior to and throughout the i.v. infusion period.
Serial blood samples were collected via the jugular cannula at regular intervals throughout the infusion to characterize the blood concentration-time profile and confirm the steady-state blood concentrations had been achieved (C blood ). Blood samples (ca. 90 ml) were collected into tubes containing K 2 EDTA as anticoagulant, a 50-ml aliquot diluted with an equal volume of purified water and stored at approximately 280°C prior to analysis by HPLC-MS/MS. For the determination of brain ECF concentrations (Cu brain,ECF ) and probe recovery, serial aCSF samples were collected at regular intervals throughout the infusion period into a refrigerated fraction collector maintained at 4°C.
Following the end of the infusion, rats were exsanguinated under anesthesia (Euthatal [Merial Animal Health, Woking, UK] administered via the jugular vein cannula), CSF samples were collected from the cisterna magna for determination of CSF concentration (C CSF ), and the brains were removed. A 50-ml aliquot of exsanguinated blood samples was diluted with an equal volume of deionized water and stored at approximately 280°C prior to analysis by HPLC-MS/MS for determination of drug blood concentration. Another aliquot of exsanguinated blood samples was diluted with an equal volume of phosphatebuffered saline (PBS) for determination of the unbound drug fraction (fu blood ) by equilibrium dialysis and stored at 4°C. Brains were rinsed in chilled saline, and superficial blood vessels were removed, weighed, and homogenized with an equal volume of PBS. Brain homogenate was stored as either weighed aliquots (50 ml) at 280°C for determination of total brain concentration (C brain ) by HPLC-MS/MS, or as bulk at 4°C for determination of the unbound drug fraction (fu brain ) by equilibrium dialysis. Total brain concentrations were corrected for residual blood volume using a value of 15 ml/g as the vascular space (Brown et al., 1986) .
Probe Calibration. Probes were calibrated by retrodialysis in vivo with probe recoveries being calculated as follows:
where C out is the concentration in the dialysate, C in is the concentration in the perfusate, and percentage of loss is assumed to equal percentage of recovery. Similarly, probes were calibrated in vitro by loss of retrodialyser and recovery of test compound following the in vivo phase:
where C out is the concentration in the dialysate and C in is the concentration in the perfusate, and
where C out is the concentration in the dialysate and C in is the concentration in the bathing solution. Recovery values used to estimate Cu brain,ECF were selected based on the most appropriate method for each test compound.
Bioanalysis of Blood, CSF, ECF, and Brain Homogenate Samples. Aliquots of blood, brain, and CSF (50 ml) and microdialyste (22.5 ml) were extracted by means of protein precipitation (250 ml) containing a suitable internal standard. The performance of internal standard chosen was considered to be acceptable by the analyzers in all cases. Calibration curve ranges and analytical conditions are detailed in Supplemental Table 2 . Quality control samples (n 5 3 per concentration) accompanied the calibration curves at the assay limit of quantification (LLQ; 4 Â LLQ), the geometric mean of the calibration range, and the upper limit of quantification. All samples were analyzed by means of LC-MS/MS on a PE-Sciex API-4000 tandem quadrupole mass spectrometer (Applied Biosystems, Ontario, Canada) using a Turbo V Ionspray operated at a source temperature of 700°C (80 psi of nitrogen). Samples (3-10 ml) were injected using a CTC Analytics HTS Pal autosampler (Presearch, Hitchin, UK).
Equilibrium Dialysis Experiments. A 96-well equilibrium dialysis apparatus was used to determine the free fraction in the blood and brain for each drug (HT Dialysis LLC, Gales Ferry, CT). Membranes (3-kDA cutoff) were conditioned in deionized water for 40 minutes, followed by conditioning in 80:20 deionized water:ethanol for 20 minutes, and then rinsed in deionized water before use. Rat brains were obtained fresh on the day of the experiment and were homogenized with PBS to a final composition of 1:2 brain:PBS by means of ultrasonication (Tomtec Autogiser; Receptor Technologies, Adderbury, Oxon, UK) in an ice bath. Diluted brain homogenate was spiked with the test compound (1000 ng/g), and 100-ml aliquots (n 5 6 replicate determinations) were loaded into the 96-well equilibrium dialysis plate. Dialysis versus PBS (100 ml) was carried out for 5 hours in a temperature-controlled incubator at 37°C (Stuart Scientific, Watford, UK) using an orbital microplate shaker at 125 rpm (Stuart Scientific). At the end of the incubation period, aliquots of brain homogenate or PBS were transferred to Matrix ScreenMate tubes (Matrix Technologies, Hudson, NH), and the composition in each tube was balanced with control fluid such that the volume of PBS to brain was the same. Sample extraction was performed by the addition of 200 ml of acetonitrile containing an internal standard. Samples were allowed to mix for 15 minutes and then centrifuged at 2465 Â g in 96-well blocks for 20 minutes (Eppendorf 5810R; VWR International, Poole, Dorset, UK). The unbound fraction was determined as the ratio of the peak area in buffer to that in brain, with correction for dilution factor according to following equation (Kalvass and Maurer, 2002) :
where D 5 dilution factor in brain homogenate, and fu apparent is the measured free fraction of diluted brain tissue. MDR1-MDCKII Cell Passive Membrane Permeability and P-gp Transport Measurements. Cell culture media, bovine serum albumin, medium supplements (L-glutamine, 20 mM sodium bicarbonate, nonessential amino acids, sodium pyruvate, colchicine), and Hanks' balanced salt solution was purchased from Invitrogen (Carlsbad, CA). Transwells (12-well, 1.13-cm 2 area, 0.4-mm pores) were purchased from Costar (Cambridge, MA). Krebs-Ringer bicarbonate buffer was obtained from Sigma-Aldrich (St. Louis, MO), and drugs were supplied by GlaxoSmithKline (Stevenage, UK).
Multidrug resistance Madin-Darby canine kidney (MDR1-MDCK) type II cells were obtained from the National Institutes of Health (Bethesda, MD). Cells were maintained in minimum essential Eagle's medium containing 2 mM L-glutamine, 20 mM sodium bicarbonate, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 10% bovine serum albumin supplemented with 0.2 mM colchicine to maintain P-gp expression. For permeability experiments, cells with passage numbers 24-33 were seeded at a density of 60,000 cells/cm 2 on rat type I collagen-coated polycarbonate membranes in 12-well transwell plates. The experiments were performed on the eighth day after seeding. Prior to the permeation assay, the transepithelial electrical resistance (TEER) was measured on each cell monolayer using an Endohm Voltameter (World Precision Instruments, Sarasota, FL). The MDR1-MDCK cell systems used in transport experiments had a high TEER value ranging from 1800 to 2000 V cm 2 , which differs from lower TEER MDR1-MDCK models often used in CNS screens (Braun et al., 2000) . The permeability assay buffer was Hanks' balanced salt solution containing 10 mM HEPES and 15 mM glucose at pH 7.4. The cells were dosed on the apical side and basolateral side, and incubated at 37°C with 5% CO 2 and 90% relative humidity under shaking conditions (150 rpm) to reduce the influence of the unstirred water layer. The test compounds were prepared to a final concentration of 3 mM. In the P-gp inhibition assays, the cells were incubated with 2 mM GF 120918A (9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl) ethyl]phenyl]-4-acridinecarboxamide), a known P-gp inhibitor. Drug permeation was tested in two directions, apical-to-basolateral (A-to-B) and basolateral-toapical (B-to-A), in triplicate. Sampling was done 60 minutes after dosing. The apparent permeability coefficient (P app ) was calculated as follows:
where dCr/dt is the slope of the cumulative concentration in the receiver compartment versus time in mM/s, Vr is the volume of transport assay buffer in the receiver compartment, A is the area of the cell monolayer, and C 0 is the drug concentration in the dosing solution. The recovery of most compounds exceeded 80%. The bidirectional efflux ratio was determined as follows:
Efflux ratio 5 P app ðB-AÞ P app ðA-BÞ (6) P-gp efflux was confirmed by determining the bidirectional efflux ratio in the presence of elacridar (2 mM) and observing an efflux ratio of unity. Data Analysis. Total blood concentrations were measured in serial blood samples. Total C blood values were determined using the mean measured blood concentrations during the final hours of the i.v. infusion once steady state had been achieved. Total C brain values were measured in terminal brain homogenate samples, and C CSF was measured in terminal CSF samples. C brain was used with C blood to determine the CNS penetration of test compounds.
The unbound brain-to-blood concentration, K p,uu , was determined as follows, where Cu represents the unbound concentration in the relevant compartment:
Molecular and Physicochemical Descriptors. Acidic and basic ionization constants (pKa) were calculated from ChemAxon version 5.4.1.1 (ChemAxon Kft, Budapest, Hungary). cLogP and cLogD7.4 were calculated using the ChemAxon .NET 5.11.4.30. Topological polar surface area was calculated by the method of P. Ertl, and only N and O are considered as polar atoms (Ertl et al., 2000) . Hydrogen bond acceptor and hydrogen bond donor were calculated with any N, O, or S atoms with a lone pair, excluding basic amines and anilines, etc. Table 1 shows rat and mouse brain K p,uu values and in vitro P-gp efflux ratios (ERs) for a series of CNS-targeted molecules. K p,uu covers a 320-fold range from 0.022 (ergotamine) to 7.1 (perphenazine). Atenolol is included as a marker of the extravascular brain volume (K p,uu 5 0.012; Summerfield et al., 2007) . Individual K p and unbound fraction values are supplied in Supplemental Table 3 .
Results
In Fig. 1 , K p,uu is plotted versus increasing in situ BBB permeability (data reported in Summerfield et al., 2008) and shows no strong correlation between rate of drug passage across the BBB and the extent of distribution at steady state (Hammarlund-Udenaes et al., 2008; Summerfield and Dong, 2013) . Several compounds that are characterized have low K p,uu values (,0.5) and are identified as substrates for human P-gp in vitro (ER . 2): sumatriptan (K p,uu 5 0.034, ER 5 2.9), primidone (K p,uu 5 0.38, ER 5 3.6), amoxapine (K p,uu 5 0.35, ER 5 4.1), rizatriptan (K p,uu 5 0.043, ER 5 8.4), metoclopramide (K p,uu 5 0.40, ER 5 13), risperidone (K p,uu 5 0.20, ER 5 21), thiothixene (K p,uu 5 0.13, ER 5 48), ergotamine (K p,uu 5 0.022, ER 5 50), and mesoridazine (K p,uu 5 0.10, ER 5 87). Gabapentin is also associated with a relatively low rat brain K p,uu value of 0.44, although it is subject to facilitated transport (Su et al., 1995) .
Several of the CNS-targeted molecules possess tricyclic groups (Fig. 2) and were also characterized by rat brain K p,uu values greater than 2; this includes the phenothiazine moiety of chlorpromazine, perphenazine, thioridazine, and trifluorperazine. Related tricyclic ring systems lead to K p,uu . 2 for clozapine, olanzapine, doxepin, imipramine, loxepin, mianserin, and mirtazapine. For the tricyclic CNS drugs where K p,uu is close to or less than unity, BBB efflux appears to occur. From steady-state CNS penetration studies using wild-type and genetic P-gp knockout mice, maprotiline is identified as a moderate P-gp substrate (Table 1) . Indeed, the mouse brain K p,uu of maprotiline increases from 1.42 to 3.06 between the wild-type and mdr1a/b(2/2) knockout mice, which suggests the presence of competing efflux and uptake processes. Similarly, amitriptyline has been reported as a P-gp substrate based on in vivo knockout studies (Uhr et al., 2000 (Uhr et al., , 2007 Abaut et al., 2009 ). Sun et al. (2006) reported multiple transporters involved in the passage of carbamazepine across cultured rat brain microvascular endothelial cells. For fluphenazine, the rat brain K p,uu is 1.58 but increases to over 6 in both mdr1a/b(1/1) and mdr1a/b(2/2) mice (Table 1) . Amoxapine and thiothixene are identified as P-gp substrates in vitro (Table 1) but are not entirely excluded from the rat brain since their respective K p,uu values are 0.35 and 0.13. The brain K p,uu for tacrine was determined as 1.61 in rats (Table 1) , increasing to over 2 in mice (Table 1) . Striatal extracellular fluid concentrations of tacrine were shown to decrease with increasing dose (Sung et al., 2005) , and transporter studies in human embryonic kidney 293 cells suggested the involvement of multiple cationic transporter systems in rats. Quetiapine and midazolam are the only tricyclic examples in this compound set where the rat brain K p,uu values are Uptake of CNS Drugs and Candidates across the BBB close to unity but show no propensity for efflux by P-gp in vitro or in vivo (Table 1) . Currently, no further information is reported in the literature to suggest whether quetiapine is subject to efflux via another transport system. Eight additional compounds were characterized by K p,uu values greater than 2 (Fig. 2) : amantadine, atomoxetine, bupropion, fluoxetine, lamotrigine, memantine, pergolide, and sertraline. Of these, amantadine and memantine share a common tricyclodecanamine moiety, and a concentration dependency on the BBB permeability of memantine has been reported that arises from facilitated transport via a cationic proton antiporter (Mehta et al., 2013) .
The rat brain K p,uu of lamotrigine was determined as 4.86 in this study, which accords with it being a substrate for OCT1 in human brain endothelial cells (Dickens et al., 2012) . It is noteworthy that the mouse brain K p,uu for lamotrigine is much closer to unity (Table 1) , but there is no indication of efflux by P-gp substrate (Table 1) . The unbound blood fractions in both rat and mouse are comparable for lamotrigine (0.28 and 0.29, respectively), as are the unbound brain fractions (0.27 and 0.20, respectively). Taken together, these data may support a species difference in the BBB transport of lamotrigine between rat and mouse. The rat brain K p,uu of fluoxetine was determined as 5.23 in this study. In contrast, results from Doran et al. (2005) suggested that the mouse brain K p,uu was close to unity in both mdr1a/b(1/1) or mdr1a/b(2/2) mice. Fluoxetine is subject to an extremely high degree of nonspecific brain tissue binding, and fu brain was measured as 0.00094 in mice (Doran et al., 2005) but was around 4-fold higher in this study at 0.0040. Since greater variability is likely to be seen at the lowest extremity of the fu brain assay, the high K p,uu could be an experimental artifact in this study, although comparable data in a single species are not available for fluoxetine. It is noteworthy that the structural analog atomoxetine was characterized by a rat brain K p,uu of 2.13 and increased from 2.35 to 4.10 in the P-gp knockout mouse model (Table 1) . Conversely, in vivo microdialysis determined the K p,uu of atomoxetine as 0.7 (Kielbasa et al., 2009 ). The unbound blood/plasma fractions are comparable between these studies, although K p differs almost 2-fold between this study (K p 5 19) and the following microdialysis (K p 5 11).
Pergolide is an ergot derivative characterized by a rat brain K p,uu value of 3.19 and was not identified as a P-gp substrate, in agreement with another reported study (Vautier et al., 2008) . Although few reports are available on the transport of ergotamine itself in vivo, an ergot-containing analog, lysergic acid, was seen to accumulate in frog choroid plexus cells by an Na/K ATPase-dependent process with the characteristics of active transport (Wright, 1972) . Mulac et al. (2012) also reported ergotamine as a breast cancer resistance protein substrate based on in vitro observations, and hence, bidirectional transport may be occurring. Last, sertraline was measured with a rat brain K p,uu of 2.67 and a mouse brain K p,uu around 4. In contrast, Doran et al. (2005) reported the mouse brain K p,uu of sertraline as 1.5 following subcutaneous administration, rather than i.v. infusion to steady-state used in this study.
Mdr1a/b Mouse Model. Brain penetration data collected in mice highlight several CNS-targeted molecules where the brain K p,uu increases markedly above unity following P-gp knockout (Table 1) ; these drugs are citalopram (K p,uu 5 4.58), risperidone (K p,uu 5 2.29), ziprasidone (K p,uu 5 7.17), digoxin (K p,uu 5 3.41), mesoridazine (K p,uu 5 2.79), thiothixene (K p,uu 5 3.67), metoclopramide (K p,uu 5 6.23), and venlafaxine (K p,uu 5 7.59). Mesoridazine and thiothixene both possess the phenothiazine moiety but are also strong P-gp substrates. For citalopram, Bundgaard et al. (2012) reported an increase in the mouse brain K p,uu to 4.8 in P-gp-deficient mice. Although the primary focus of this work was on a P-gp species difference, the putative involvement of an uptake mechanism has been recognized (Rochat et al., 1999) .
For risperidone, the mouse brain K p increased from 0.78 to 8.02 in the study reported by Doran et al. (2005) , which equates a change in K p,uu from 0.26 to 2.63, respectively, when correcting for the fu plasma and fu brain data cited in the same study. In contrast, Bundgaard et al. (2012) reported K p,uu values around unity in P-gp knockout rats and mice following infusion to steady state. A structural analog, ziprasidone, was characterized by a mouse brain K p,uu value of 7.17 in our present study, which may point to a potential mechanism for facilitated uptake for both structurally related drugs. Digoxin 
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overdose is known to induce CNS symptoms (Kelly and Smith, 1992) , and despite P-gp playing a key role in maintaining low brain concentrations of digoxin, high affinity for a specific organic anion transporter may help to increase K p,uu above unity in the mdr1a/b(2/2) model (Noé et al., 1997; Taub et al., 2011) . For metoclopramide, the rat brain K p,uu (0.40) in this study agrees with another report (0.37) (Doran et al., 2012) , but no other comparative work in P-gp-deficient species is available, nor could any literature reports be found that suggest the involvement of carrier-mediated transport for metoclopramide. Work in transfected human embryonic kidney 293 cells has shown metoclopramide is a substrate for OATP1A2 along with several triptans, although this transporter does not have rodent homologs (Cheng et al., 2012) . For venlafaxine, the K p,uu was determined to be 1.91 in the rat brain, 4.87 in mdr1a/b(1/1) mice, and 7.59 in mdr1a/b(2/2) mice. Recently, its structural isomer tramadol was characterized by a brain K p,uu of 2.3 following microdialysis, and subsequent mechanistic studies suggested carrier-mediated transport by means of a proton-coupled organic cation antiporter (Kitamura et al., 2014) .
In Vivo Microdialysis. To cross-reference the in vitro determinations of Cu brain (e.g., C brain Â fu brain,homogenate ), two high brain K p,uu drugs were selected for rat brain microdialysis (clozapine and bupropion). Acetaminophen was also included as a control because K p,uu was measured as being close to unity. Clozapine and bupropion were also selected, as they differ greatly in terms of their unbound blood fractions (0.066 vs. 0.391) and unbound brain fractions (0.011 vs.0.171). The blood and brain ECF unbound concentration-time profiles for bupropion are displayed in Fig. 3 . The corresponding concentration-time profiles for acetaminophen and clozapine were reported previously (Summerfield and Dong, 2013) .
For acetaminophen, the unbound concentrations were comparable between blood (4.97 6 1.00 mM), brain ECF (3.52 6 0.52 mM), and cisternal CSF (4.95 6 0.27 mM) ( Table 2 ). Following microdialysis, the rat brain K p,uu of acetaminophen was determined as 0.73 6 0.16. Equilibrium dialysis of ex vivo blood and brain homogenates from the rats infused with acetaminophen realized a mean unbound blood fraction of 0.741 6 0.128 and a mean unbound brain fraction of 0.724 6 0.050. These values were used to correct the total concentrations in blood and brain to unbound concentrations, which yields an ex vivo rat K p,uu of 0.613 6 0.136.
In the case of bupropion, the rat brain K p,uu was determined as 3.3 6 1.7 following microdialysis (range 2.35-5.77). The particular rat associated with the highest K p,uu value was also characterized by an approximately 2-fold larger brain K p (18 vs. 10) and 2-fold higher brain ECF concentrations (2.64 vs. 1.28 mM). The unbound concentrations of bupropion were higher in brain ECF (1.62 6 0.69 mM) relative to both the blood (0.504 6 0.066 mM) and cisternal CSF (0.250 6 0. 053 mM). Equilibrium dialysis of ex vivo blood and brain homogenates from the rats infused with bupropion realized a mean unbound blood fraction of 0.537 6 0.056 and a mean unbound brain fraction of 0.149 6 0.008. Using the total concentrations in brain and correcting for the ex vivo brain binding gave a comparable ex vivo rat brain K p,uu of 3.08 6 0.71.
For clozapine, the rat brain K p,uu was determined as 2.2 6 0.2 following microdialysis, consistent with the data presented in Table 1 . The initial brain ECF measurements for clozapine were below the quantification limit of the analytical method, but concentrations were measurable at steady state (albeit with more variability than bupropion and acetaminophen). The unbound concentration of clozapine was highest in cisternal CSF (0.156 6 0.005 mM), followed by brain ECF (0.077 6 0.008 mM), and then lowest in blood (0.036 6 0.002 mM). Equilibrium dialysis of ex vivo blood and brain homogenates from the rats infused with clozapine realized a mean unbound blood fraction of 0.059 6 0.012 and a mean unbound brain fraction of 0.0109 6 0.0015. Using the total concentrations in brain and correcting for the ex vivo brain binding gave a comparable ex vivo rat brain K p,uu of 3.18 6 0.50. K p,uu Assessments of CNS Drug Candidates from Lead Optimization. Rat brain K p,uu data were available for 771 proprietary compounds synthesized against CNS targets, of which K p,uu was $2 for 41 compounds (5.5%) and $3 for 19 compounds. Of these, CNS penetration measurements were taken at steady state for four compounds, whereas the remainder were from acute studies. Uptake of CNS Drugs and Candidates across the BBB physicochemical properties of these high K p,uu compounds. Generally, the number of hydrogen bond donors and acceptors was low (median values of 1 and 2, respectively), and many were characterized by reasonably acidic pKa values. Of these CNS discovery candidates, a wide range of structures were noted that were mostly distinct from the CNS compound set, presumably because of the novel CNS targets being prosecuted in lead optimization. Four of these proprietary molecules were characterized by fused ring systems, but in general, the chemotypes were not comparable to those detailed in the CNS compound set.
In comparison, the CNS-targeted compound set was characterized by 19 out of 53 (36%) with K p,uu $ 2, and 15 (28%) with K p,uu $ 3. Analysis of physicochemical properties associated with rat K p,uu values revealed that drugs with K p,uu . 2 had reduced topological polar surface area as compared with drugs with K p,uu , 0.5 or 0.5 # K p,uu # 2 (Supplemental Fig. 1 ; Supplemental Table 1 ). However, the compound set is not large enough to form a definitive conclusion. A more detailed analysis in relationships between compound physicochemical properties and rat K p,uu values in a larger data set was published elsewhere (Zhang et al., 2016) . Selection of the compound set was originally conceived to represent the span of physiochemical properties of molecules targeting the CNS, e.g., rather than maximizing the span of targets themselves. The compound set comprises agonists, antagonists, inhibitors, and reuptake inhibitors of various important CNS receptors, such as dopamine (e.g., clozapine and perphenazine), serotonin (e.g., risperidone and citalopram), gamma aminobutyric acid (e.g., midazolam and meprobamate), noradrenaline (e.g., amoxapine and venlafaxine), and monoamine oxidase (e.g., selegiline and isocarboxazid). Many of these CNS drugs were also approved in an era when pharmacology screening played a more prominent role in progressing early leads, whereas today's paradigm relies far more heavily on batteries of in vitro Drug Metabolism and Pharmacokinetics (DMPK) screens to triage drug candidates. Evidently, during that period, the concept of K p,uu had not been conceived, and hence serendipity played a large part in selecting drug candidates subject to uptake across the BBB.
Discussion
The introduction of the K p,uu parameter has provided new insights into the processes that occur during drug passage across the BBB. This work focused on molecules in which there is evidence to support facilitated passage across the BBB-namely, where K p,uu is markedly greater than unity. However, the present study also highlights examples in which there are clearly at least two transport processes acting in opposing directions, such that the overall K p,uu is closer to unity. Examples of this are citalopram, metoclopramide, and thiothixene.
Donepezil poses an interesting example of potential crossspecies differences in K p,uu . Being a modest P-substrate in the mouse, the donepezil K p,uu increases from 1.19 and 2.64 (Table 1) , whereas Kim et al. (2010) noted concentrationdependent transport of donepezil and proposed this to be mediated by organic cation transporters, such as the choline transport system. Recently, we reported the minipig K p of donepezil as 14.9, identified as compound "L" following a 1-hour i.v. infusion at a dose of 1 mg/kg (Summerfield and Dong, 2013) . The unbound fractions in plasma and brain were 0.260 6 0.027 and 0.162 6 0.017, realizing a minipig brain K p,uu of 7.2. In humans, the brain Positron Emission Tomography (PET) biodistribution of 11 C-donepezil was approximately 20 in healthy elderly subjects (Okamura et al., 2008) , which translates to a K p,uu estimate of 10, after correcting for plasma protein binding (Nagy et al., 2004) and assuming the brain tissue binding is comparable across species (Summerfield et al., 2008) .
Given the interplay between passive transfer across the BBB and the potential for competing efflux, experimental conditions are likely to play an important part in whether a drug candidate is identified as a substrate for drug uptake. Absolute K p,uu values may be dependent on the circulating unbound concentration bathing the BBB (e.g., the dose administered) and whether any of these transport processes are subject to saturation. At the limit, brain K p,uu would approach unity if the transport processes are saturated and passive diffusion becomes the dominant process of drug passage across the BBB. Interestingly, a review by the International Transporter Consortium noted that, other than carrier-mediated transfer via P-gp, decreases or increases in brain K p were generally less than a few-fold in many transporter knockout models (Kalvass et al., 2013; Tweedie et al., 2013) .
It is important to recognize not only that K p,uu is a steadystate parameter, but also that it is most often generated indirectly, e.g., by correcting the total brain concentration for the unbound brain fraction. Hence, it is imperative that steady-state conditions are achieved to accurately reflect the brain K p,uu , which is exemplified in Fig. 4 . The BBB initiative that led to many of the publications reported by GSK performed a large battery of in vivo and in vitro tests on this set of CNS-targeted molecules, including both acute (oral) and steady-state (i.v.) brain distribution studies. Acute studies were included because many of the early estimates of brain distribution during lead optimization were derived from shortterm pharmacology models, whereas steady-state brain distribution studies were supplemented for promising molecules. Comparison of the acute and steady-state brain K p data highlighted a strong correlation between the two data sets; however, the slope of correlation was approximately 0.5 rather than unity, the steady-state brain K p values generally being higher than the acute K p values. Figure 4 shows this correlation in terms of K p,uu , where the difference is most marked for the higher K p,uu compounds. Similarly, the mouse data set originally reported by Doran et al. (2005) has been a valuable resource for understanding brain distribution in terms of unbound concentrations, although only one compound was described by a brain K p,uu greater than 2 in the mdr1a/b(1/1) mouse (e.g., methylphenidate; Liu et al., 2008) . In the corresponding mdr1a/b(2/2) strain, eight compounds are characterized by K p,uu $ 2, e.g., cyclobenzaprine, fluvoxamine, hydrocodone, methylphenidate, metoclopramide, nortriptyline, propoxyphene, and risperidone. These K p,uu values were determined from the area under the curve measurements following subcutaneous dosing over 5 hours (concentration sampling from four time points: 0.5, 1, 2.5, or 5 hours). The acute studies shown in Fig. 4 were performed following oral dosing with blood and brain samples collected up to 8 hours.
Many CNS drugs possessing tricyclic functions, such as chlorpromazine and olanzapine, appear to undergo facilitated transfer across the rodent BBB. An uptake mechanism for clozapine across HL-60 cells has been proposed previously (Henning et al., 2002) , but further work is required to characterize whether there is a common carrier-mediated system or whether this structural element would be useful in other CNS-targeted drug candidates. Since the pH values of blood and brain ECF are comparable, these increases in brain K p,uu for tricyclic molecules are unlikely to be the result of ion trapping, and in general, their acidities and basicities vary widely (see Supplemental Data File 1; Supplemental Table S2 ).
Not all of the examples highlighted in this study (where K p,uu is significantly greater than unity) can be supported by literature data, but perhaps this is unsurprising. Drug efflux, particularly P-gp, has blighted drug discovery because the inherent reduction in brain penetration leads to a corresponding reduction in efficacy. However this is not the case for uptake across the BBB; higher unbound brain concentrations would still lead to an efficacious effect in vivo, albeit at lower doses. The traditional K p measurement would have provided no indication of uptake, and discovery pharmacokinetic/ pharmacodynamic models are rarely refined enough to highlight efficacy at an unexpectedly low dose. Indeed, prior to the inception of K p,uu , carrier-mediated transport may have only been speculated when the extent of brain penetration appeared at odds with the physicochemical properties (e.g., gabapentin and lamotrigine). In the case of lipophilic molecules, which readily traverse the BBB, a difference of a fewfold in brain penetration arising from facilitated uptake mechanism would not be discernible without the determination of K p,uu .
Predicting difference in K p,uu across species remains a significant challenge, especially when only rodent data or acute brain distribution studies are performed. So how does the industry obtain better estimates for the human K p,uu ? Take an example such as donepezil, where literature data suggest K p,uu is far higher in humans than would be anticipated from the rodent data. The early estimates of the human dose are highly sensitive to the value of brain K p,uu ; a 3-fold change in K p,uu would attenuate the corresponding human dose prediction 3-fold (assuming unbound brain concentrations are driving efficacy). In vitro BBB models for human K p,uu have been reported based on stem cells (Cecchelli et al., 2014) , and the promise is immense for helping progress the next generation of CNS drugs. Although the number of reported in vitro and in vivo human brain K p,uu compounds is currently small, it is noteworthy that both bupropion and lamotrigine showed human brain K p,uu estimates close to unity. However, the estimates for human K p,uu were made using CSF concentrations, whereas this may not be a reliable surrogate for a variety of reasons (de Lange, 2013) . A question also remains concerning the junction tightness in human cellbased systems. Low TEER values could lead to increased Uptake of CNS Drugs and Candidates across the BBB directional flux of drug across the in vitro BBB system; in particular, K p,uu values tend to be only a few-fold greater than unity.
In summary, the introduction of K p,uu has enabled a deeper insight into the factors affecting the unbound concentration gradient across the BBB. In vivo microdialysis studies on clozapine and bupropion confirmed the corresponding in vitro K p,uu estimates (Table 2) . Clearly, examples such as citalopram and maprotiline demonstrate that a measured brain K p,uu around unity need not necessarily be the result of a purely passive transfer process (Table 1) . Differences in brain distribution across species, concentration dependency of brain distribution (in vitro or in vivo), or evidence of uptake from other pharmacokinetic information may highlight the potential for uptake across the BBB.
